NewGenIvf Group (NASDAQ:NIVF) Director Buys 222,223 Shares

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung acquired 222,223 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were acquired at an average price of $1.50 per share, with a total value of $333,334.50. Following the acquisition, the director owned 222,223 shares in the company, valued at approximately $333,334.50. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock. The shares were purchased at an average price of $1.00 per share, for a total transaction of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung purchased 500,000 shares of NewGenIvf Group stock. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Trading Down 1.4%

NIVF stock opened at $1.33 on Wednesday. NewGenIvf Group Limited has a one year low of $1.15 and a one year high of $1,539.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. The firm’s fifty day moving average is $2.96 and its 200 day moving average is $11.34.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NIVF. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.